scholarly journals Comparative Analysis of Paper-based and Web-based Versions National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy-Breast Cancer Symptom Index (NFBSI-16) Questionnaire in Breast Cancer Patients: Randomised Crossover Study. (Preprint)

10.2196/18269 ◽  
2020 ◽  
Author(s):  
Jinfei Ma ◽  
Zihao Zou ◽  
Emmanuel Eric Pazo ◽  
Salissou Moutari ◽  
Ye Liu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Comparative Analysis ◽  
Cancer Therapy ◽  
National Comprehensive Cancer Network ◽  
Cancer Patients ◽  
Functional Assessment ◽  
Breast Cancer Patients ◽  
Symptom Index ◽  
Web Based ◽  
Cancer Network

scholarly journals Comparative Analysis of Paper-based and Web-based Versions NFBSI-16 (National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy-Breast Cancer Symptom Index) Questionnaire in Breast Cancer Patients: Randomised, crossover study. (Preprint)

2020 ◽  
Author(s):  
Jinfei Ma ◽  
Zihao Zou ◽  
Emmanuel Eric Pazo ◽  
Feng Jin
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Chinese Language ◽  
Breast Cancer Patients ◽  
Systematic Treatment ◽  
Symptom Index ◽  
Web Based ◽  
Test Retest Reliability ◽  
Cancer Network ◽  
The Web

BACKGROUND Breast cancer remains the most common neoplasm diagnosed amongst women in China and globally. Health-related questionnaire assessments in research and clinical oncology settings have gained prominence. National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy-Breast Cancer Symptom Index (NFBSI-16) is a rapid and powerful tool to help evaluate the disease or treatment-related symptoms, both physical and emotional, in patients with breast cancer for clinical and research need. Prevalence of individual smartphones and social apps provide a potential electronic approach to administrating questionnaire; however, the reliability of NFBSI-16 in electronic format has not been assessed. OBJECTIVE This study aimed to assess the reliability of web-based measurement of NFBSI-16 in the Chinese language in breast cancer patients undergoing systematic treatment. METHODS We recruited patients with breast cancer under systematic treatment to complete both paper- and web-based questionnaires. Patients were randomly assigned to group A (paper- based first and web-based second) or group B (web- based first and paper-based second). A total of 354 patients included in the analysis successfully completed both versions of the NFBSI-16 questionnaire in Chinese language. Descriptive sociodemographic characteristics, reliability and agreement rates for single items, subscale, and total score were analyzed using Wilcoxon test. Lin’s concordance correlation coefficient (CCC), Spearman and Kendall tau rank correlation were used to assess test-retest reliability. RESULTS Test-retest reliability was excellent with CCCs 0.94 for the total NFBSI-16 score. Highly significant correlations were documented for all 4 subscales, 16 individual items, and total NFBSI-16 score. Mean differences of the test and re-test were all close to zero (≤0.06). A majority of the participants in this study preferred the web-based (72%, n=255) over the paper-based version. CONCLUSIONS The web-based version of the NFBSI-16 questionnaire is reliable for patients with breast cancer and demonstrated highly significant correlations with the paper-based version in all items, subscales and the total score. The web-based version of the NFBSI-16 questionnaire is an excellent tool for monitoring individual breast cancer patients under treatment, also as a majority of participants preferred it over paper-based version.

scholarly journals Managing Cancer and Living Meaningfully (CALM) Intervention on Chemotherapy-Related Cognitive Impairment in Breast Cancer Survivors

2020 ◽  
Vol 19 ◽  
pp. 153473542093845
Author(s):  
Ke Ding ◽  
Xiuqing Zhang ◽  
Jingjing Zhao ◽  
He Zuo ◽  
Ziran Bi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cognitive Impairment ◽  
Psychological Distress ◽  
Cognitive Function ◽  
Cancer Therapy ◽  
Cancer Patients ◽  
Functional Assessment ◽  
Breast Cancer Survivors ◽  
Breast Cancer Patients ◽  
Before And After

Objective: To evaluate the effectiveness and feasibility of Managing Cancer and Living Meaningfully (CALM), which is used to reduce chemotherapy-related cognitive impairment (CRCI), relieve psychological distress, and improve quality of life (QOL) in Chinese breast cancer survivors (BCs). Methods: Seventy-four BCs were enrolled in this study. All patients were randomly assigned to either the CALM group or the care as usual (CAU) group. All patients were evaluated by the Functional Assessment of Cancer Therapy–Cognitive Function (FACT-Cog), Distress Thermometer (DT), and the Functional Assessment of Cancer Therapy–Breast (FACT-B) before and after CALM or CAU application to BCs with CRCI. We compared the differences in all these scores between the CALM group and the control group and analyzed the correlation between cognitive function and QOL. Results: Compared with the CAU group, the performance of the CALM group on the FACT-Cog, DT, and FACT-B showed significant differences before and after CALM ( t = −18.909, −5.180, −32.421, P = .000, .000, .000, respectively). Finally, there was a positive correlation between cognitive function and QOL in breast cancer patients before ( r = 0.579, P = .000) and after ( r = 0.797, P = .000) treatment. Conclusions: The present results indicated that CALM has salutary effects on the improvement of cognitive impairment and QOL and relieves psychological distress in breast cancer patients, which may be due to a positive correlation between psychological distress and cognitive function or QOL.

Adherence to National Comprehensive Cancer Network Guidelines for BRCA testing among breast cancer patients.

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. e13624-e13624 ◽  
Author(s):  
Nadine M. Tung ◽  
Priyanka J. Bobbili ◽  
Temitope O. Olufade ◽  
Maral DerSarkissian ◽  
Rachel Bhak ◽  
...  
Keyword(s):  
Breast Cancer ◽  
National Comprehensive Cancer Network ◽  
Cancer Patients ◽  
Breast Cancer Patients ◽  
Brca Testing ◽  
Cancer Network

scholarly journals What Are the Most Important Symptoms and Concerns of Patients with Indolent Non-Hodgkin's Lymphoma? Content Validation of the National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy Lymphoma Symptom Index-18 (NFLymSI-18)

Blood ◽  
2016 ◽  
Vol 128 (22) ◽  
pp. 4792-4792
Author(s):  
Karen Kaiser ◽  
Sara Shaunfield ◽  
Kimberly Webster ◽  
Karen Keating ◽  
Lara Boyken ◽  
...  
Keyword(s):  
Side Effects ◽  
Cancer Therapy ◽  
National Comprehensive Cancer Network ◽  
Hair Loss ◽  
Functional Assessment ◽  
Content Validity ◽  
Research Funding ◽  
Symptom Index ◽  
Treatment Side Effects ◽  
Cancer Network

Abstract Background and aims: Although indolent B-cell non-Hodgkin's lymphoma (iNHL) may occur without symptoms, the presence of symptoms often provides an important signal of disease activity and may negatively affect quality of life. Thus, valid measures of disease symptoms are important for clinical trials and patient care. We aimed to assess whether the National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy Lymphoma Symptom Index-18 (NFLymSI-18) addresses a representative set of iNHL symptoms, treatment side effects, and emotional concerns. Methods: Eligible patients had a confirmed iNHL diagnosis and had received one or more lines of treatment. Patients were recruited during clinic visits; informed consent was obtained from interested patients. Data were collected via face-to-face semi-structured interviews in which patients described their symptoms, treatment side effects, and emotional concerns related to iNHL. Qualitative data were analyzed using NVivo10 and results were mapped to the NFLymSI-18 to assess content validity. Patient and expert input from the development of the NFLymSI-18 and literature on iNHL symptoms were reviewed to further inform the content validity assessment. Results: Data saturation was obtained by the 18th interview. Mean age of the 18 participants was 66.8 years (range 49-85). Fifty-six percent of the sample was male. Most participants (66.7%) had a college or advanced degree. When asked to describe their iNHL symptoms, patients most often discussed swelling (n=14), fatigue (n=12), and pain (n=8). The following symptoms were also mentioned by three patients each: anxiety, appetite loss, rash, sleep disruption, trouble breathing, and malaise. Treatment side effects spontaneously mentioned most often were fatigue (N=10), nausea (n=9), hair loss (N=8), cognitive problems (N=6), and weight loss (N=6). Emotional responses frequently mentioned included gratitude for life (N=11), worry (N=11), and feeling down (N=8). Mapping of NFLymSI-18 content to these patient concerns showed the instrument includes all of the most frequently-mentioned concerns. Some less frequently-mentioned concerns (i.e., rash, trouble breathing, malaise, fevers, hair loss, feeling down) are not covered by the instrument. Conclusion and Summary: Patients with iNHL reported a wide range of disease related symptoms; however, swelling, fatigue and pain were most common. This study supports the representativeness of existing NFLymSI-18 items for patients with iNHL. In particular, the instrument shows strong validity for the most commonly referenced patient symptoms. The diversity of additional symptoms reported by patients is consistent with the heterogeneous symptomology of iNHL. These less-frequently-endorsed symptoms, side effects, and emotional concerns, could be added to the NFLymSI-18 if one wished to have a more inclusive assessment of concerns associated with iNHL. Disclosures Keating: Bayer Pharmaceuticals, Inc.: Employment. Cella:GlaxoSmithKline: Consultancy, Research Funding; Abbvie, Inc.: Consultancy, Research Funding; Bristol-Meyers Squibb: Consultancy, Research Funding; Facit.org: Other: President; Alexion, Inc., Astellas, Biogen Idec, Celgene, Clovis Oncology, Inc., Daiichi Sankyo, Eli Lilly, Evidera, Inc., Exelixis, Fiborgen, Genetech, Helsinn Therapeutics, Inc., Immunogen, Ipsen Pharma, Janssen, Lexicon Pharmaceuticals, Inc., Merck, Novartis, Onc: Consultancy, Research Funding; Bayer Pharmaceuticals, Inc.: Consultancy, Research Funding.

Sign in / Sign up

Export Citation Format

Share Document